Revision to German Pharmaceutical Act finalised and published
This article was originally published in SRA
After massive criticism from the pharmaceutical industry, the revision to Germany’s Pharmaceutical Act was amended allowing the industry to keep at least a limited right to choose how and which wholesalers they supply. This compromise on the compulsory supply to wholesalers was reached following long and controversial debates.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.